Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BLUDIGO | Provepharm | N-216264 RX | 2022-07-08 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
bludigo | New Drug Application | 2023-01-20 |
indigo carmine | unapproved drug other | 2021-04-15 |
Expiration | Code | ||
---|---|---|---|
INDIGOTINDISULFONATE SODIUM, BLUDIGO, PROVEPHARM SAS | |||
2027-07-08 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | — | 1 | 1 | 1 | 8 | 11 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | 1 | 7 | 8 |
Neoplasms | D009369 | — | C80 | — | — | — | 1 | 6 | 7 |
Leukemia | D007938 | — | C95 | 1 | — | 3 | 1 | 1 | 6 |
Promyelocytic leukemia acute | D015473 | — | C92.4 | — | — | 2 | 1 | 1 | 4 |
Esophageal neoplasms | D004938 | — | C15 | — | — | — | 1 | 2 | 3 |
Ureteral obstruction | D014517 | HP_0006000 | — | — | — | — | 1 | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | — | — | 1 | — | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | — | — | 1 | — | 1 |
Duodenal neoplasms | D004379 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriasis | D011565 | EFO_0000676 | L40 | — | 6 | 2 | — | 1 | 7 |
Adenoma | D000236 | — | — | — | — | 1 | — | 5 | 6 |
Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 2 | — | — | 2 |
Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | 2 | — | — | 2 |
Enuresis | D004775 | — | R32 | — | — | 2 | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | 1 | — | — | 2 |
Recurrence | D012008 | — | — | — | — | 1 | — | 1 | 2 |
Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | — | 1 | 2 |
Stress urinary incontinence | D014550 | HP_0010992 | — | — | — | 1 | — | — | 1 |
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hereditary nonpolyposis colorectal neoplasms | D003123 | EFO_0007354 | — | — | 1 | — | — | 4 | 5 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
Eczema | D004485 | HP_0000964 | L30.9 | — | 2 | — | — | — | 2 |
Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 1 |
Anus neoplasms | D001005 | EFO_0003835 | C21 | — | 1 | — | — | — | 1 |
Rhabdomyosarcoma | D012208 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Embolism | D004617 | — | — | 1 | — | — | — | 5 | 6 |
Colonic polyps | D003111 | — | K63.5 | 1 | — | — | — | 4 | 5 |
Pulmonary embolism | D011655 | HP_0002204 | I26 | 1 | — | — | — | 4 | 5 |
Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 6 | 6 |
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 6 | 6 |
Colitis | D003092 | EFO_0003872 | K52.9 | — | — | — | — | 6 | 6 |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 4 | 4 |
Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 4 | 4 |
Syndrome | D013577 | — | — | — | — | — | — | 4 | 4 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 3 | 3 |
Peptic esophagitis | D004942 | EFO_1001095 | — | — | — | — | — | 3 | 3 |
Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 3 | 3 |
Polyps | D011127 | EFO_0000662 | — | — | — | — | — | 3 | 3 |
Drug common name | Indigotindisulfonate sodium |
INN | — |
Description | Indigo carmine, or 5,5′-indigodisulfonic acid sodium salt, is an organic salt derived from indigo by aromatic sulfonation, which renders the compound soluble in water. It is approved for use as a food colorant in the U.S and E.U. to produce a blue color. It has the E number E132. It is also a pH indicator.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1/C(=C2\Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21.[Na+].[Na+] |
PDB | — |
CAS-ID | 860-22-0 |
RxCUI | — |
ChEMBL ID | CHEMBL2105023 |
ChEBI ID | 31695 |
PubChem CID | 5284351 |
DrugBank | DB11577 |
UNII ID | — |